GLP1-S (Semaglutide)

Overview

Semaglutide, listed as GLP1-S in research vendor catalogs, is a GLP-1 receptor agonist with structural modifications that extend its half-life to approximately one week. It is one of the most studied peptides in the metabolic research space, with extensive clinical trial data supporting its effects on weight management and glycemic control.

Mechanism of Action

Semaglutide binds to and activates the GLP-1 receptor with high affinity. An acylated fatty acid chain enables albumin binding, dramatically extending circulatory half-life. GLP-1 receptor activation in the hypothalamus reduces appetite and food intake. Peripheral effects include slowed gastric emptying, enhanced insulin secretion, and suppressed glucagon release.

Research Context

Clinical trials demonstrated significant weight reduction (up to 15-17% of body weight) in study participants. Semaglutide also showed cardiovascular benefits including reduced major adverse cardiovascular events. It is one of the most commercially successful peptide therapeutics in history.

Key Research Areas

Considerations for Researchers

Due to its commercial pharmaceutical status, research-grade semaglutide from peptide vendors differs from pharmaceutical products. Verify purity and identity through independent testing. Store lyophilized at -20C.